ODTX Fail-to-Deliver
Odyssey Therapeutics, Inc. (ODTX) operates in the Healthcare sector, specifically the Biotechnology industry, with a market capitalization near $496.7M, listed on NASDAQ, employing roughly 100 people, carrying a beta of 0.00 to the broader market. Odyssey Therapeutics, Inc. Led by Gary D. Glick, public since 2026-05-08.
Fail-to-deliver (FTD) data from the SEC tracks settlement failures where shares were not delivered within the standard settlement period. Persistent FTDs may indicate naked short selling or settlement issues and are monitored by regulators.
- Latest Date
- 2026-05-14
- Latest FTD Quantity
- 332
- Latest Price
- $17.94
- 30-Day Avg FTD
- 59.7K
- 30-Day Total FTD
- 238.9K
Showing 4 days of SEC fail-to-deliver data for Odyssey Therapeutics, Inc..
Learn how fails-to-deliver is reported and how to read the data →
Frequently asked ODTX fail to deliver questions
- What is the latest ODTX fail-to-deliver count?
- As of May 14, 2026, Odyssey Therapeutics, Inc. (ODTX) fail-to-deliver quantity is 332 shares, with a 4-day average of 59.7K shares. The SEC publishes FTD data twice monthly: first-half data at month-end, second-half around the 15th of the following month.
- What is the FTD aggregate net balance?
- FTD figures represent the aggregate net balance in NSCC's Continuous Net Settlement (CNS) system, not the gross failed-share count. The published numbers run 2-6 weeks stale relative to the underlying settlement date.
- How do ODTX FTDs affect options pricing?
- Persistent FTDs flag hard-to-borrow conditions that distort put-call parity: in HTB names, synthetic long stock (long call + short put at the same strike) trades below the frictionless-parity price by approximately the borrow rebate. The discount equals the lending revenue forgone by holding the synthetic instead of actual shares. Reg SHO threshold-list inclusion follows from sustained FTD persistence.